Spero Therapeutics, Inc.
SPRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -53.8% | 113.6% | 1,482.4% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -101.7% | 50.4% | 100% | 100% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -151.1% | 26.2% | -88.4% | -2,839.4% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -142.9% | 22% | -95.5% | -2,923.6% |
| EPS Diluted | -1.27 | 0.43 | -1.23 | -2.91 |
| % Growth | -395.3% | 135% | 57.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |